Cargando…

Serum biochemical markers in lung cancer.

The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of con...

Descripción completa

Detalles Bibliográficos
Autores principales: Burt, R. W., Ratcliffe, J. G., Stack, B. H., Cuthbert, J., Kennedy, R. S., Corker, C. S., Franchimont, P., Spilg, W. G., Stimson, W. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1978
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009624/
https://www.ncbi.nlm.nih.gov/pubmed/77672
_version_ 1782136152562597888
author Burt, R. W.
Ratcliffe, J. G.
Stack, B. H.
Cuthbert, J.
Kennedy, R. S.
Corker, C. S.
Franchimont, P.
Spilg, W. G.
Stimson, W. H.
author_facet Burt, R. W.
Ratcliffe, J. G.
Stack, B. H.
Cuthbert, J.
Kennedy, R. S.
Corker, C. S.
Franchimont, P.
Spilg, W. G.
Stimson, W. H.
author_sort Burt, R. W.
collection PubMed
description The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of controls) were found as follows: carcinoembryonic antigen (CEA), 17%; pregnancy-associated alpha-macroglobulin (PAM), 16%; casein 14%; human chorionic gonadotrophin (HCG) 6%; alpha-foetoprotein (AFP), 1.5%. The prevalence of elevated CEA levels (but not other markers) was higher in patients with evidence of extra-thoracic tumour spread (23%) mainly due to anaplastic tumours and adenocarcinomas. A degree of concordance of elevated marker levels occurred with CEA, HCG, casein and AFP, but there was a striking discordance of elevated CEA and PAM levels. Simultaneous assays of CEA and PAM will detect the majority of patients with elevations of any of the markers studied, and are likely to be the most useful biochemical markers in following the response of lung tumours to therapy.
format Text
id pubmed-2009624
institution National Center for Biotechnology Information
language English
publishDate 1978
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20096242009-09-10 Serum biochemical markers in lung cancer. Burt, R. W. Ratcliffe, J. G. Stack, B. H. Cuthbert, J. Kennedy, R. S. Corker, C. S. Franchimont, P. Spilg, W. G. Stimson, W. H. Br J Cancer Research Article The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of controls) were found as follows: carcinoembryonic antigen (CEA), 17%; pregnancy-associated alpha-macroglobulin (PAM), 16%; casein 14%; human chorionic gonadotrophin (HCG) 6%; alpha-foetoprotein (AFP), 1.5%. The prevalence of elevated CEA levels (but not other markers) was higher in patients with evidence of extra-thoracic tumour spread (23%) mainly due to anaplastic tumours and adenocarcinomas. A degree of concordance of elevated marker levels occurred with CEA, HCG, casein and AFP, but there was a striking discordance of elevated CEA and PAM levels. Simultaneous assays of CEA and PAM will detect the majority of patients with elevations of any of the markers studied, and are likely to be the most useful biochemical markers in following the response of lung tumours to therapy. Nature Publishing Group 1978-05 /pmc/articles/PMC2009624/ /pubmed/77672 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Burt, R. W.
Ratcliffe, J. G.
Stack, B. H.
Cuthbert, J.
Kennedy, R. S.
Corker, C. S.
Franchimont, P.
Spilg, W. G.
Stimson, W. H.
Serum biochemical markers in lung cancer.
title Serum biochemical markers in lung cancer.
title_full Serum biochemical markers in lung cancer.
title_fullStr Serum biochemical markers in lung cancer.
title_full_unstemmed Serum biochemical markers in lung cancer.
title_short Serum biochemical markers in lung cancer.
title_sort serum biochemical markers in lung cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009624/
https://www.ncbi.nlm.nih.gov/pubmed/77672
work_keys_str_mv AT burtrw serumbiochemicalmarkersinlungcancer
AT ratcliffejg serumbiochemicalmarkersinlungcancer
AT stackbh serumbiochemicalmarkersinlungcancer
AT cuthbertj serumbiochemicalmarkersinlungcancer
AT kennedyrs serumbiochemicalmarkersinlungcancer
AT corkercs serumbiochemicalmarkersinlungcancer
AT franchimontp serumbiochemicalmarkersinlungcancer
AT spilgwg serumbiochemicalmarkersinlungcancer
AT stimsonwh serumbiochemicalmarkersinlungcancer